SMARCA4-deficient Malignant Tumors clinical trials at UCSF
1 in progress, 0 open to eligible people
Showing trials for
Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
Sorry, in progress, not accepting new patients
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
San Francisco 5391959, California 5332921 and other locations
Our lead scientists for SMARCA4-deficient Malignant Tumors research studies include Alyssa Reddy.
Last updated: